Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMWY0TN)

• Drug Name: LICOAGROCHACONE A Drug Info
• Synonyms: licochalcone a; 58749-22-7; Licochalcone-A; UNII-JTV5467968; 3-Dimethylallyl-4,4'-dihydroxy-6-methoxychalcone; CHEMBL139702; C21H22O4; JTV5467968; (E)-3-[5-(1,1-Dimethyl-2-propenyl)-4-hydroxy-2-methoxyphenyl]-1-(4-hydroxyphenyl)-2-propen-1-one; Licochalcone-A, Synthetic; Q-100677; (E)-3-[5-(1,1-dimethylallyl)-4-hydroxy-2-methoxy-phenyl]-1-(4-hydroxyphenyl)prop-2-en-1-one; 2-Propen-1-one, 3-(5-(1,1-dimethyl-2-propenyl)-4-hydroxy-2-methoxyphenyl)-1-(4-hydroxyphenyl)-, (E)-

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 5318998
  ChEBI ID: CHEBI:125689
  CAS Number: CAS 58749-22-7
  TTD Drug ID: DMWY0TN

Molecule-Related Drug Atlas

Drug(s) Targeting PTPN1 messenger RNA (PTPN1 mRNA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[4]
TRYPAN BLUE	DM4NTMO	Ophthalmic surgery injury	PK97	Approved	[5]
URSOLIC ACID	DM4SOAW	Metabolic syndrome x	5C50-5D2Z	Phase 2	[6]
ISIS 113715	DMUPD4G	Type-2 diabetes	5A11	Phase 2	[7]
ISIS-PTP1Brx	DMJGVXT	Type-2 diabetes	5A11	Phase 2	[8]
ERTIPROTAFIB	DMJXEV7	Type-2 diabetes	5A11	Terminated	[9]
Acetate Ion	DMD08RH	Discovery agent	N.A.	Investigative	[10]
B-Octylglucoside	DMMO75G	Discovery agent	N.A.	Investigative	[10]
2-Methyl-2,4-Pentanediol	DMD45CU	Discovery agent	N.A.	Investigative	[10]
Double Oxidized Cysteine	DM6TU84	Discovery agent	N.A.	Investigative	[10]

Drug(s) Affected By Cytochrome P450 1A2 (CYP1A2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Zolmitriptan	DM1IB4Q	Migraine	8A80	Approved	[11]
Rofecoxib	DM3P5DA	Osteoarthritis	FA00-FA05	Approved	[11]
Etoricoxib	DM6A4NW	Rheumatoid arthritis	FA20	Approved	[11]
Capsaicin	DMGMF6V	Back pain	ME84.Z	Approved	[12]
Hesperetin	DMKER83	High blood cholesterol level	5C80.00	Approved	[13]
Stiripentol	DMMSDOY	Dravet syndrome	8A61.11	Approved	[14]
Nifedipine	DMSVOZT	Angina pectoris	BA40	Approved	[15]
Zileuton	DMVRIC2	Allergic asthma	CA23.0	Approved	[16]
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[17]
Clonidine	DM6RZ9Q	Attention deficit hyperactivity disorder	6A05.Z	Approved	[18]

Drug(s) Affected By Cytochrome P450 2E1 (CYP2E1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fomepizole	DM6VOWQ	Athylene glycol or methanol poisoning	NE61	Approved	[19]
Ademetionine	DMYQDBO	Hepatic fibrosis	DB93.0	Approved	[20]
Theophylline	DMRJFN9	Bronchitis	CA20	Approved	[18]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[21]
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[22]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[23]
Phenobarbital	DMXZOCG	Cluster headache	8A81.0	Approved	[24]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[25]
Didanosine	DMI2QPE	Human immunodeficiency virus infection	1C62	Approved	[18]
Thioridazine	DM35M8J	Schizophrenia	6A20	Approved	[26]

Drug(s) Affected By Cytochrome P450 3A4 (CYP3A4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Eplerenone	DMF0NQR	Heart failure	BD10-BD13	Approved	[27]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[28]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[29]
Voriconazole	DMAOL2S	Aspergillosis	1F20	Approved	[30]
Proguanil	DMBL79I	Malaria	1F40-1F45	Approved	[31]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[31]
Loratadine	DMF3AN7	Allergy	4A80-4A85	Approved	[32]
Nelfinavir mesylate	DMFX6G8	N. A.	N. A.	Approved	[33]
Capsaicin	DMGMF6V	Back pain	ME84.Z	Approved	[34]
Axitinib	DMGVH6N	Renal cell carcinoma	2C90	Approved	[35]

Drug(s) Affected By Cytochrome P450 2C8 (CYP2C8)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[36]
Cyclophosphamide	DM4O2Z7	Advanced cancer	2A00-2F9Z	Approved	[37]
Lovastatin	DM9OZWQ	Arteriosclerosis	BD40	Approved	[36]
Ifosfamide	DMCT3I8	Adult central nervous system germ cell tumor		Approved	[37]
Sulfinpyrazone	DMEV954	Gout	FA25	Approved	[38]
Loratadine	DMF3AN7	Allergy	4A80-4A85	Approved	[36]
Zafirlukast	DMHNQOG	Asthma	CA23	Approved	[36]
Ethinyl Estradiol	DMODJ40	Acne vulgaris	ED80	Approved	[36]
Sorafenib	DMS8IFC	Adenocarcinoma	2D40	Approved	[39]
Dabrafenib	DMX6OE3	Melanoma	2C30	Approved	[40]

Drug(s) Affected By Cytochrome P450 2D6 (CYP2D6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[41]
Paliperidone	DM7NPJS	Psychotic disorder	6A20-6A25	Approved	[42]
Dopamine	DMPGUCF	Acromegaly	5A60.0	Approved	[43]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[44]
Oxatomide	DM1F42Z	Hay fever	CA08.00	Approved	[45]
Cinacalcet	DMCX0K3	Hyperparathyroidism	5A51	Approved	[46]
Capsaicin	DMGMF6V	Back pain	ME84.Z	Approved	[12]
Pentamidine	DMHZJCG	African trypanosomiasis	1F51	Approved	[31]
Quinidine	DMLPICK	N. A.	N. A.	Approved	[47]
Buprenorphine	DMPRI8G	Opioid dependence	6C43.2Z	Approved	[48]

Drug(s) Affected By Cytochrome P450 2C9 (CYP2C9)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[28]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[49]
Dapsone	DM4LT8A	Acne vulgaris	ED80	Approved	[31]
Voriconazole	DMAOL2S	Aspergillosis	1F20	Approved	[30]
Capsaicin	DMGMF6V	Back pain	ME84.Z	Approved	[12]
Zafirlukast	DMHNQOG	Asthma	CA23	Approved	[50]
Niclosamide	DMJAGXQ	Cestodes infection	1F70-1F76	Approved	[31]
Eicosapentaenoic acid/docosa-hexaenoic acid	DMMUCG4	Hypertriglyceridemia	5C80.1	Approved	[51]
Fluconazole	DMOWZ6B	Cryptococcal meningitis		Approved	[30]
Quinine	DMSWYF5	Malaria	1F40-1F45	Approved	[31]

Drug(s) Affected By Cytochrome P450 2C19 (CYP2C19)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[28]
Thioridazine	DM35M8J	Schizophrenia	6A20	Approved	[26]
Voriconazole	DMAOL2S	Aspergillosis	1F20	Approved	[30]
Chloramphenicol	DMFXEWT	Bacterial infection	1A00-1C4Z	Approved	[52]
Capsaicin	DMGMF6V	Back pain	ME84.Z	Approved	[12]
Pentamidine	DMHZJCG	African trypanosomiasis	1F51	Approved	[31]
Stiripentol	DMMSDOY	Dravet syndrome	8A61.11	Approved	[14]
Quinine	DMSWYF5	Malaria	1F40-1F45	Approved	[31]
Desipramine	DMT2FDC	Attention deficit hyperactivity disorder	6A05.Z	Approved	[26]
Amitriptyline	DMK7F9S	Depression	6A70-6A7Z	Approved	[18]

Drug(s) Affected By Cytochrome P450 1B1 (CYP1B1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Flutamide	DMK0O7U	Prostate cancer	2C82.0	Approved	[53]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[54]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[55]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[56]
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[57]
Melatonin	DMKWFBT	Depression	6A70-6A7Z	Approved	[58]
Vitamin A	DMJ2AH4	Night blindness	9D45	Approved	[59]
Amodiaquine	DME4RA8	Malaria	1F40-1F45	Approved	[60]
Daunorubicin	DMQUSBT	Acute monocytic leukemia		Approved	[61]
Pantothenic acid	DM091H2	Vitamin deficiency	5B55-5B71	Approved	[62]

Drug(s) Affected By Pescadillo homolog (PES1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selenium	DM25CGV	N. A.	N. A.	Approved	[63]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[64]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[65]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[66]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[67]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[68]
Tocopherol	DMBIJZ6	N. A.	N. A.	Phase 2	[63]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[69]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[70]

Drug(s) Affected By CCN family member 1 (CCN1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[54]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[71]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[72]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[73]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[74]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[75]
Methylprednisolone	DM4BDON	Acute adrenal insufficiency		Approved	[71]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[76]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[77]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[78]

Drug(s) Affected By Tumor necrosis factor receptor superfamily member 10B (TNFRSF10B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[79]
Gemcitabine	DMSE3I7	Anterior urethra cancer		Approved	[80]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[81]
Bepridil	DM0RKS4	Chronic/stable angina	BA40.1	Approved	[82]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[83]
Selenium	DM25CGV	N. A.	N. A.	Approved	[84]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[79]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[85]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[86]
Dactinomycin	DM2YGNW	Adult kidney Wilms tumor		Approved	[85]

Drug(s) Affected By Baculoviral IAP repeat-containing protein 5 (BIRC5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[87]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[88]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[89]
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[90]
Etretinate	DM2CZFA	Keratosis	ED56	Approved	[91]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[92]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[93]
Lapatinib	DM3BH1Y	Breast cancer	2C60-2C65	Approved	[94]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[95]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[96]

Drug(s) Affected By Serine/threonine-protein kinase LATS1 (LATS1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[97]
Chlorpromazine	DMBGZI3	Acute intermittent hepatic porphyria	5C58.11	Approved	[98]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[64]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[99]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[65]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[100]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[101]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[102]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[68]
Napabucasin	DMDZ6Q3	Colorectal cancer	2B91.Z	Phase 3	[103]

Drug(s) Affected By Urokinase-type plasminogen activator (PLAU)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dactinomycin	DM2YGNW	Adult kidney Wilms tumor		Approved	[104]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[86]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[105]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[74]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[106]
Cyclophosphamide	DM4O2Z7	Advanced cancer	2A00-2F9Z	Approved	[104]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[107]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[108]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[99]
Atorvastatin	DMF28YC	Acute coronary syndrome	BA41	Approved	[109]

Drug(s) Affected By Cyclin-dependent kinase 1 (CDK1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[110]
Mechlorethamine	DM0CVXA	Chronic myelogenous leukaemia	2A20.0	Approved	[111]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[87]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[112]
Selenium	DM25CGV	N. A.	N. A.	Approved	[113]
Etretinate	DM2CZFA	Keratosis	ED56	Approved	[91]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[114]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[115]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[72]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[116]

Drug(s) Affected By Poly polymerase 1 (PARP1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[117]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[118]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[119]
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[90]
Citalopram	DM2G9AE	Acute coronary syndrome	BA41	Approved	[120]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[121]
Imipramine	DM2NUH3	Depression	6A70-6A7Z	Approved	[120]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[122]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[123]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[124]

Drug(s) Affected By Apoptosis regulator Bcl-2 (BCL2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sevoflurane	DMC9O43	Anaesthesia	9A78.6	Approved	[125]
Docetaxel	DMDI269	Advanced cancer	2A00-2F9Z	Approved	[126]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[127]
Gemcitabine	DMSE3I7	Anterior urethra cancer		Approved	[128]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[18]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[117]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[129]
Mechlorethamine	DM0CVXA	Chronic myelogenous leukaemia	2A20.0	Approved	[130]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[131]
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[132]

Drug(s) Affected By G2/mitotic-specific cyclin-B1 (CCNB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[110]
Mechlorethamine	DM0CVXA	Chronic myelogenous leukaemia	2A20.0	Approved	[111]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[133]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[112]
Selenium	DM25CGV	N. A.	N. A.	Approved	[113]
Etretinate	DM2CZFA	Keratosis	ED56	Approved	[91]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[121]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[134]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[92]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[135]

Drug(s) Affected By Ribosomal protein S6 kinase beta-1 (RPS6KB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[136]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[137]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[138]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[139]
Trametinib	DM2JGQ3	Melanoma	2C30	Approved	[140]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[141]
Romiplostim	DM3U7SZ	Thrombocytopenia	3B64	Approved	[142]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[143]
Glucosamine	DM4ZLFD	Osteoarthritis	FA00-FA05	Approved	[144]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[145]

Drug(s) Affected By G1/S-specific cyclin-D1 (CCND1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Indomethacin	DMSC4A7	Bursitis		Approved	[146]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[147]
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[132]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[148]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[149]
Talazoparib	DM1KS78	Breast cancer	2C60-2C65	Approved	[150]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[151]
Selenium	DM25CGV	N. A.	N. A.	Approved	[63]
Ribavirin	DMEYLH9	Hepatitis C virus infection	1E51.1	Approved	[152]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[153]

Drug(s) Affected By Tumor necrosis factor receptor superfamily member 6 (FAS)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[154]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[54]
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[90]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[155]
Epinephrine	DM3KJBC	Acute asthma	CA23	Approved	[156]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[157]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[158]
Fructose	DM43AN2	Vomiting	MD90	Approved	[159]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[154]
Cyclophosphamide	DM4O2Z7	Advanced cancer	2A00-2F9Z	Approved	[160]

Drug(s) Affected By Mitogen-activated protein kinase 3 (MAPK3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[161]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[162]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[163]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[131]
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[164]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[165]
Secobarbital	DM14RF5	Epilepsy	8A60-8A68	Approved	[166]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[167]
Fexofenadine	DM17ONX	Allergic rhinitis	CA08.0	Approved	[168]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[169]

Drug(s) Affected By Mitogen-activated protein kinase 1 (MAPK1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[170]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[162]
Carvedilol	DMHTEAO	Chronic heart failure	BD1Z	Approved	[171]
Paclitaxel	DMLB81S	Breast carcinoma		Approved	[172]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[173]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[161]
Urokinase	DM0GOUD	Myocardial infarction	BA41-BA43	Approved	[18]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[81]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[131]
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[164]

Drug(s) Affected By CCN family member 2 (CCN2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[117]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[174]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[175]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[73]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[176]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[177]
Methylprednisolone	DM4BDON	Acute adrenal insufficiency		Approved	[71]
Chlorpromazine	DMBGZI3	Acute intermittent hepatic porphyria	5C58.11	Approved	[98]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[178]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[179]

Drug(s) Affected By RAC-alpha serine/threonine-protein kinase (AKT1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Capivasertib	DM9SKW8	Breast cancer	2C60-2C65	Approved	[180]
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[181]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[182]
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[132]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[183]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[139]
Imiquimod	DM1TMA3	Alopecia areata	ED70.2	Approved	[184]
Selenium	DM25CGV	N. A.	N. A.	Approved	[63]
Methimazole	DM25FL8	Hyperthyroidism	5A02	Approved	[185]
Ribavirin	DMEYLH9	Hepatitis C virus infection	1E51.1	Approved	[152]

Drug(s) Affected By Cyclin-dependent kinase inhibitor 1 (CDKN1A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[186]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[187]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[133]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[88]
Talazoparib	DM1KS78	Breast cancer	2C60-2C65	Approved	[150]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[54]
Etretinate	DM2CZFA	Keratosis	ED56	Approved	[91]
Prednisone	DM2HG4X	Acute asthma	CA23	Approved	[188]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[121]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[79]

Drug(s) Affected By Caspase-3 (CASP3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sevoflurane	DMC9O43	Anaesthesia	9A78.6	Approved	[189]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[190]
Lovastatin	DM9OZWQ	Arteriosclerosis	BD40	Approved	[191]
Cidofovir	DMA13GD	Cytomegalovirus infection	1D82	Approved	[192]
Docetaxel	DMDI269	Advanced cancer	2A00-2F9Z	Approved	[193]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[194]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[195]
Mannitol	DMSCDY9	Bronchiectasis	CA24	Approved	[196]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[197]
Aprepitant	DM053KT	Depression	6A70-6A7Z	Approved	[198]

Drug(s) Affected By Mitogen-activated protein kinase 8 (MAPK8)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[199]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[200]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[201]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[202]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[203]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[204]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[205]
Glucosamine	DM4ZLFD	Osteoarthritis	FA00-FA05	Approved	[206]
Vinblastine	DM5TVS3	Advanced cancer	2A00-2F9Z	Approved	[203]
Ethacrynic acid	DM60QMR	Edema	MG29	Approved	[207]

Drug(s) Affected By Mitogen-activated protein kinase 9 (MAPK9)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[200]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[208]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[203]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[209]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[210]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[211]
Vinblastine	DM5TVS3	Advanced cancer	2A00-2F9Z	Approved	[203]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[212]
Sorbitol	DMAN0DE	Constipation	DD91.1	Approved	[213]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[214]

Drug(s) Affected By Dual specificity mitogen-activated protein kinase kinase 4 (MAP2K4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[115]
Dactinomycin	DM2YGNW	Adult kidney Wilms tumor		Approved	[215]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[216]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[217]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[218]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[66]
Menthol	DMG2KW7	Back pain	ME84.Z	Approved	[219]
Sorafenib	DMS8IFC	Adenocarcinoma	2D40	Approved	[220]
Indomethacin	DMSC4A7	Bursitis		Approved	[221]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[222]

Drug(s) Affected By Caspase-9 (CASP9)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Lovastatin	DM9OZWQ	Arteriosclerosis	BD40	Approved	[223]
Mannitol	DMSCDY9	Bronchiectasis	CA24	Approved	[224]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[117]
Mechlorethamine	DM0CVXA	Chronic myelogenous leukaemia	2A20.0	Approved	[130]
Leuprorelin acetate	DM15HAT	Prostate cancer	2C82.0	Approved	[225]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[226]
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[90]
Meloxicam	DM2AR7L	Arthritis	FA20	Approved	[227]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[228]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[229]

Drug(s) Affected By Protein kinase C epsilon type (PRKCE)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Deoxycholic acid	DM3GYAL	Subcutaneous fat disorder	EF02	Approved	[230]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[231]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[74]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[106]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[107]
Indomethacin	DMSC4A7	Bursitis		Approved	[232]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[233]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[234]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[68]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[235]

Drug(s) Affected By Apoptosis regulator BAX (BAX)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sevoflurane	DMC9O43	Anaesthesia	9A78.6	Approved	[125]
Aprepitant	DM053KT	Depression	6A70-6A7Z	Approved	[198]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[117]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[129]
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[154]
Leuprorelin acetate	DM15HAT	Prostate cancer	2C82.0	Approved	[225]
Talazoparib	DM1KS78	Breast cancer	2C60-2C65	Approved	[150]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[208]
Meloxicam	DM2AR7L	Arthritis	FA20	Approved	[236]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[121]

Drug(s) Affected By Serine/threonine-protein kinase 4 (STK4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[211]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[218]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[237]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[66]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[101]
Irinotecan	DMP6SC2	Adenocarcinoma	2D40	Approved	[238]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[239]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[68]
Bortezomib	DMNO38U	Leukemia		Approved	[240]
Tocopherol	DMBIJZ6	N. A.	N. A.	Phase 2	[63]

Drug(s) Affected By Dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[241]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[242]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[112]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[99]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[218]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[101]
Irinotecan	DMP6SC2	Adenocarcinoma	2D40	Approved	[243]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[244]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[235]
Resveratrol	DM3RWXL	Giant cell arteritis	4A44.2	Phase 3	[245]

Drug(s) Affected By Caspase-8 (CASP8)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Lovastatin	DM9OZWQ	Arteriosclerosis	BD40	Approved	[246]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[247]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[248]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[81]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[249]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[250]
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[90]
Selenium	DM25CGV	N. A.	N. A.	Approved	[63]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[228]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[251]

Drug(s) Affected By Bcl-2 homologous antagonist/killer (BAK1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Mechlorethamine	DM0CVXA	Chronic myelogenous leukaemia	2A20.0	Approved	[252]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[208]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[253]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[115]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[254]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[106]
Levamisole	DM5EN79	Parasitic infection	1D0Y-1G2Z	Approved	[255]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[256]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[257]
Promethazine	DM6I5GR	Hyperemesis gravidarum		Approved	[258]

Drug(s) Affected By Caspase-10 (CASP10)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[242]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[259]
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[90]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[86]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[260]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[231]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[261]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[211]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[262]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[217]

Drug(s) Affected By Bcl2-associated agonist of cell death (BAD)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Paclitaxel	DMLB81S	Breast carcinoma		Approved	[263]
Aprepitant	DM053KT	Depression	6A70-6A7Z	Approved	[198]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[81]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[264]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[265]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[266]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[231]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[267]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[268]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[269]

Drug(s) Affected By Tumor necrosis factor receptor superfamily member 25 (TNFRSF25)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[112]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[115]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[211]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[270]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[269]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[77]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[65]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[25]
Menthol	DMG2KW7	Back pain	ME84.Z	Approved	[219]
Capsaicin	DMGMF6V	Back pain	ME84.Z	Approved	[271]

Drug(s) Affected By Bcl-2-binding component 3, isoforms 3/4 (BBC3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[112]
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[90]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[92]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[272]
Dactinomycin	DM2YGNW	Adult kidney Wilms tumor		Approved	[273]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[72]
Penicillamine	DM40EF6	Cystinuria	5C60.2	Approved	[274]
Nefazodone	DM4ZS8M	Major depressive disorder	6A70.3	Approved	[275]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[276]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[277]

Drug(s) Affected By Solute carrier organic anion transporter family member 1B1 (SLCO1B1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Enalapril	DMNFUZR	Congestive heart failure	BD10	Approved	[278]
Lovastatin	DM9OZWQ	Arteriosclerosis	BD40	Approved	[279]
Bosentan	DMIOGBU	Pulmonary arterial hypertension	BB01.0	Approved	[280]
Repaglinide	DM5SXUV	Diabetic complication	5A2Y	Approved	[281]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[282]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[283]
Cholic Acid	DM7OKQV	Cholelithiasis	DC11	Approved	[284]
Ursodeoxycholic acid	DMCUT21	Cholelithiasis	DC11	Approved	[284]
Hydroxyurea	DMOQVU9	Chronic myelogenous leukaemia	2A20.0	Approved	[285]
Irinotecan	DMP6SC2	Adenocarcinoma	2D40	Approved	[286]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
PTPN1 messenger RNA (PTPN1 mRNA)	TTELIN2	PTN1_HUMAN	Inhibitor	[1]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Apoptosis regulator BAX (BAX)	OTAW0V4V	BAX_HUMAN	Gene/Protein Processing	[2]
Apoptosis regulator Bcl-2 (BCL2)	OT9DVHC0	BCL2_HUMAN	Gene/Protein Processing	[2]
Baculoviral IAP repeat-containing protein 5 (BIRC5)	OTILXZYL	BIRC5_HUMAN	Gene/Protein Processing	[2]
Bcl-2 homologous antagonist/killer (BAK1)	OTDP6ILW	BAK_HUMAN	Gene/Protein Processing	[2]
Bcl-2-binding component 3, isoforms 3/4 (BBC3)	OTUAXDAY	BBC3B_HUMAN	Gene/Protein Processing	[2]
Bcl2-associated agonist of cell death (BAD)	OT63ERYM	BAD_HUMAN	Gene/Protein Processing	[2]
Caspase-10 (CASP10)	OTE6J88E	CASPA_HUMAN	Gene/Protein Processing	[2]
Caspase-3 (CASP3)	OTIJRBE7	CASP3_HUMAN	Gene/Protein Processing	[2]
Caspase-8 (CASP8)	OTA8TVI8	CASP8_HUMAN	Gene/Protein Processing	[2]
Caspase-9 (CASP9)	OTD4RFFG	CASP9_HUMAN	Protein Interaction/Cellular Processes	[3]

References

• [1] Inhibitory effect of chalcones and their derivatives from Glycyrrhiza inflata on protein tyrosine phosphatase 1B. Bioorg Med Chem Lett. 2009 Sep 1;19(17):5155-7.
• [2] Licochalcone A from licorice root, an inhibitor of human hepatoma cell growth via induction of cell apoptosis and cell cycle arrest. Food Chem Toxicol. 2018 Oct;120:407-417. doi: 10.1016/j.fct.2018.07.044. Epub 2018 Jul 25.
• [3] Licochalcone A induces apoptotic cell death via JNK/p38 activation in human nasopharyngeal carcinoma cells. Environ Toxicol. 2019 Jul;34(7):853-860. doi: 10.1002/tox.22753. Epub 2019 Apr 14.
• [4] Periodinates: a new class of protein tyrosine phosphatase inhibitors. Bioorg Med Chem Lett. 1999 Feb 8;9(3):353-6.
• [5] Evans Blue and other dyes as protein tyrosine phosphatase inhibitors. Bioorg Med Chem Lett. 2004 Apr 19;14(8):1923-6.
• [6] Cytotoxic and PTP1B inhibitory activities from Erythrina abyssinica. Bioorg Med Chem Lett. 2009 Dec 1;19(23):6745-9.
• [7] Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2009).
• [8] Clinical pipeline report, company report or official report of ISIS Pharmaceuticals.
• [9] 2-O-carboxymethylpyrogallol derivatives as PTP1B inhibitors with antihyperglycemic activity. Bioorg Med Chem Lett. 2007 Oct 1;17(19):5357-60.
• [10] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [11] In vitro inhibition of CYP1A2 by model inhibitors, anti-inflammatory analgesics and female sex steroids: predictability of in vivo interactions. Basic Clin Pharmacol Toxicol. 2008 Aug;103(2):157-65.
• [12] Effects of capsaicin and dihydrocapsaicin on human and rat liver microsomal CYP450 enzyme activities in vitro and in vivo. J Asian Nat Prod Res. 2012;14(4):382-95.
• [13] Drug interaction study of flavonoids toward CYP3A4 and their quantitative structure activity relationship (QSAR) analysis for predicting potential effects. Toxicol Lett. 2018 Sep 15;294:27-36.
• [14] Stiripentol. Expert Opin Investig Drugs. 2005 Jul;14(7):905-11.
• [15] Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: prediction of in vivo drug-drug interactions. Eur J Clin Pharmacol. 2000 Feb-Mar;55(11-12):843-52.
• [16] Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. Drug Metab Dispos. 2003 Nov;31(11):1352-60.
• [17] Predictive three-dimensional quantitative structure-activity relationship of cytochrome P450 1A2 inhibitors. J Med Chem. 2005 Jun 2;48(11):3808-15.
• [18] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
• [19] Chemical inhibitors of cytochrome P450 isoforms in human liver microsomes: a re-evaluation of P450 isoform selectivity. Eur J Drug Metab Pharmacokinet. 2011 Mar;36(1):1-16.
• [20] Inhibition of CYP2E1 catalytic activity in vitro by S-adenosyl-L-methionine. Biochem Pharmacol. 2005 Apr 1;69(7):1081-93.
• [21] Characterization of primary human hepatocytes, HepG2 cells, and HepaRG cells at the mRNA level and CYP activity in response to inducers and their predictivity for the detection of human hepatotoxins. Cell Biol Toxicol. 2012 Apr;28(2):69-87.
• [22] An in vitro model of human acute ethanol exposure that incorporates CXCR3- and CXCR4-dependent recruitment of immune cells. Toxicol Sci. 2013 Mar;132(1):131-41.
• [23] Multiple microRNAs function as self-protective modules in acetaminophen-induced hepatotoxicity in humans. Arch Toxicol. 2018 Feb;92(2):845-858.
• [24] Proteomic analysis of hepatic effects of phenobarbital in mice with humanized liver. Arch Toxicol. 2022 Oct;96(10):2739-2754. doi: 10.1007/s00204-022-03338-7. Epub 2022 Jul 26.
• [25] Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
• [26] Inhibition of cytochrome P450 enzymes participating in p-nitrophenol hydroxylation by drugs known as CYP2E1 inhibitors. Chem Biol Interact. 2004 Apr 15;147(3):331-40.
• [27] The relative role of CYP3A4 and CYP3A5 in eplerenone metabolism. Toxicol Lett. 2019 Oct 15;315:9-13.
• [28] Characterization of the structural determinants required for potent mechanism-based inhibition of human cytochrome P450 1A1 by cannabidiol. Chem Biol Interact. 2014 May 25;215:62-8.
• [29] Retinoids activate the RXR/SXR-mediated pathway and induce the endogenous CYP3A4 activity in Huh7 human hepatoma cells. Toxicol Sci. 2006 Jul;92(1):51-60.
• [30] The novel azole R126638 is a selective inhibitor of ergosterol synthesis in Candida albicans, Trichophyton spp., and Microsporum canis. Antimicrob Agents Chemother. 2004 Sep;48(9):3272-8.
• [31] Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450s. Drug Metab Dispos. 2001 Jan;29(1):30-5.
• [32] Cetirizine and loratadine-based antihistamines with 5-lipoxygenase inhibitory activity. Bioorg Med Chem Lett. 2004 Nov 15;14(22):5591-4.
• [33] Mechanism-based inactivation of CYP3A by HIV protease inhibitors. J Pharmacol Exp Ther. 2005 Feb;312(2):583-91.
• [34] Studies of the toxicological potential of capsinoids, XIII: inhibitory effects of capsaicin and capsinoids on cytochrome P450 3A4 in human liver microsomes. Int J Toxicol. 2010 Mar;29(2 Suppl):22S-6S.
• [35] Investigation of the effects of axitinib on the pharmacokinetics of loperamide and its main metabolite N-demethylated loperamide in rats by UPLC-MS/MS. Chem Biol Interact. 2019 Sep 1;310:108744. doi: 10.1016/j.cbi.2019.108744. Epub 2019 Jul 9.
• [36] Examination of 209 drugs for inhibition of cytochrome P450 2C8. J Clin Pharmacol. 2005 Jan;45(1):68-78.
• [37] Identification of the polymorphically expressed CYP2C19 and the wild-type CYP2C9-ILE359 allele as low-Km catalysts of cyclophosphamide and ifosfamide activation. Pharmacogenetics. 1997 Jun;7(3):211-21.
• [38] Essential requirements for substrate binding affinity and selectivity toward human CYP2 family enzymes. Arch Biochem Biophys. 2003 Jan 1;409(1):32-44.
• [39] Differential inhibition of human CYP2C8 and molecular docking interactions elicited by sorafenib and its major N-oxide metabolite. Chem Biol Interact. 2021 Apr 1;338:109401. doi: 10.1016/j.cbi.2021.109401. Epub 2021 Feb 5.
• [40] Dabrafenib inhibits ABCG2 and cytochrome P450 isoenzymes; potential implications for combination anticancer therapy. Toxicol Appl Pharmacol. 2022 Jan 1;434:115797. doi: 10.1016/j.taap.2021.115797. Epub 2021 Nov 13.
• [41] Human recombinant cytochrome P450 enzymes display distinct hydrogen peroxide generating activities during substrate independent NADPH oxidase reactions. Toxicol Sci. 2014 Oct;141(2):344-52. doi: 10.1093/toxsci/kfu133. Epub 2014 Jul 24.
• [42] Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone. Psychopharmacology (Berl). 1999 Dec;147(3):300-5. doi: 10.1007/s002130051171.
• [43] Effect of penicillin-based antibiotics, amoxicillin, ampicillin, and piperacillin, on drug-metabolizing activities of human hepatic cytochromes P450. J Toxicol Sci. 2016 Feb;41(1):143-6.
• [44] Cannabidiol, a major phytocannabinoid, as a potent atypical inhibitor for CYP2D6. Drug Metab Dispos. 2011 Nov;39(11):2049-56. doi: 10.1124/dmd.111.041384. Epub 2011 Aug 5.
• [45] Identification of human P450 isoforms involved in the metabolism of the antiallergic drug, oxatomide, and its kinetic parameters and inhibition constants. Biol Pharm Bull. 2005 Feb;28(2):328-34.
• [46] Pharmacokinetics of desipramine HCl when administered with cinacalcet HCl. Eur J Clin Pharmacol. 2007 Feb;63(2):159-63.
• [47] Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test. Clin Pharmacol Ther. 2001 Oct;70(4):327-35.
• [48] Interaction of buprenorphine and its metabolite norbuprenorphine with cytochromes p450 in vitro. Drug Metab Dispos. 2003 Jun;31(6):768-72.
• [49] Comparative effects of thiazolidinediones on in vitro P450 enzyme induction and inhibition. Drug Metab Dispos. 2003 Apr;31(4):439-46.
• [50] Potential of pranlukast and zafirlukast in the inhibition of human liver cytochrome P450 enzymes. Xenobiotica. 2004 May;34(5):429-38.
• [51] The inhibitory effect of polyunsaturated fatty acids on human CYP enzymes. Life Sci. 2006 Nov 25;79(26):2432-40.
• [52] Cytochrome P450 inhibition potential of new psychoactive substances of the tryptamine class. Toxicol Lett. 2016 Jan 22;241:82-94.
• [53] Association of CYP1A1 and CYP1B1 inhibition in in vitro assays with drug-induced liver injury. J Toxicol Sci. 2021;46(4):167-176. doi: 10.2131/jts.46.167.
• [54] Gene expression after treatment with hydrogen peroxide, menadione, or t-butyl hydroperoxide in breast cancer cells. Cancer Res. 2002 Nov 1;62(21):6246-54.
• [55] Convergent transcriptional profiles induced by endogenous estrogen and distinct xenoestrogens in breast cancer cells. Carcinogenesis. 2006 Aug;27(8):1567-78.
• [56] Gene expression in endometrial cancer cells (Ishikawa) after short time high dose exposure to progesterone. Steroids. 2008 Jan;73(1):116-28.
• [57] In vitro aromatic bioactivation of the weak estrogen E(2)alpha and genesis of DNA adducts. Steroids. 2005 Mar;70(3):161-72. doi: 10.1016/j.steroids.2004.11.004.
• [58] Metabolism of melatonin by human cytochromes p450. Drug Metab Dispos. 2005 Apr;33(4):489-94.
• [59] Metabolism of retinoids and arachidonic acid by human and mouse cytochrome P450 1b1. Drug Metab Dispos. 2004 Aug;32(8):840-7.
• [60] Apoptosis contributes to the cytotoxicity induced by amodiaquine and its major metabolite N-desethylamodiaquine in hepatic cells. Toxicol In Vitro. 2020 Feb;62:104669. doi: 10.1016/j.tiv.2019.104669. Epub 2019 Oct 16.
• [61] Genetic variants contributing to daunorubicin-induced cytotoxicity. Cancer Res. 2008 May 1;68(9):3161-8. doi: 10.1158/0008-5472.CAN-07-6381.
• [62] Calcium pantothenate modulates gene expression in proliferating human dermal fibroblasts. Exp Dermatol. 2009 Nov;18(11):969-78. doi: 10.1111/j.1600-0625.2009.00884.x. Epub 2009 Apr 8.
• [63] Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
• [64] THC exposure of human iPSC neurons impacts genes associated with neuropsychiatric disorders. Transl Psychiatry. 2018 Apr 25;8(1):89. doi: 10.1038/s41398-018-0137-3.
• [65] Integrating multiple omics to unravel mechanisms of Cyclosporin A induced hepatotoxicity in vitro. Toxicol In Vitro. 2015 Apr;29(3):489-501.
• [66] Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
• [67] 17-Estradiol Activates HSF1 via MAPK Signaling in ER-Positive Breast Cancer Cells. Cancers (Basel). 2019 Oct 11;11(10):1533. doi: 10.3390/cancers11101533.
• [68] Bringing in vitro analysis closer to in vivo: studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.
• [69] Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.
• [70] Low-dose Bisphenol A exposure alters the functionality and cellular environment in a human cardiomyocyte model. Environ Pollut. 2023 Oct 15;335:122359. doi: 10.1016/j.envpol.2023.122359. Epub 2023 Aug 9.
• [71] Antirheumatic drug response signatures in human chondrocytes: potential molecular targets to stimulate cartilage regeneration. Arthritis Res Ther. 2009;11(1):R15.
• [72] Simvastatin inactivates beta1-integrin and extracellular signal-related kinase signaling and inhibits cell proliferation in head and neck squamous cell carcinoma cells. Cancer Sci. 2007 Jun;98(6):890-9.
• [73] Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
• [74] Effects of ciglitazone and troglitazone on the proliferation of human stomach cancer cells. World J Gastroenterol. 2009 Jan 21;15(3):310-20.
• [75] Development of a neural teratogenicity test based on human embryonic stem cells: response to retinoic acid exposure. Toxicol Sci. 2011 Dec;124(2):370-7.
• [76] Essential role of cell cycle regulatory genes p21 and p27 expression in inhibition of breast cancer cells by arsenic trioxide. Med Oncol. 2011 Dec;28(4):1225-54.
• [77] Survival of retinal pigment epithelium after exposure to prolonged oxidative injury: a detailed gene expression and cellular analysis. Invest Ophthalmol Vis Sci. 2004 Oct;45(10):3767-77.
• [78] Large-scale in silico and microarray-based identification of direct 1,25-dihydroxyvitamin D3 target genes. Mol Endocrinol. 2005 Nov;19(11):2685-95.
• [79] Utilization of CDKN1A/p21 gene for class discrimination of DNA damage-induced clastogenicity. Toxicology. 2014 Jan 6;315:8-16. doi: 10.1016/j.tox.2013.10.009. Epub 2013 Nov 6.
• [80] Regulation of DR-5 protein and mitochondrial transmembrane potential by gemcitabine, a possible mechanism of gemcitabine-enhanced TRAIL-induced apoptosis. Oncol Rep. 2007 Sep;18(3):523-9.
• [81] Cannabidiol Modulates the Immunophenotype and Inhibits the Activation of the Inflammasome in Human Gingival Mesenchymal Stem Cells. Front Physiol. 2016 Nov 24;7:559. doi: 10.3389/fphys.2016.00559. eCollection 2016.
• [82] Amiodarone sensitizes human glioma cells but not astrocytes to TRAIL-induced apoptosis via CHOP-mediated DR5 upregulation. Neuro Oncol. 2011 Mar;13(3):267-79. doi: 10.1093/neuonc/noq195. Epub 2011 Feb 3.
• [83] Novel functional view of the crocidolite asbestos-treated A549 human lung epithelial transcriptome reveals an intricate network of pathways with opposing functions. BMC Genomics. 2008 Aug 7;9:376.
• [84] Death receptor 5 regulation during selenium-mediated apoptosis in human prostate cancer cells. Cancer Biol Ther. 2002 May-Jun;1(3):287-90. doi: 10.4161/cbt.83.
• [85] Death receptor regulation and celecoxib-induced apoptosis in human lung cancer cells. J Natl Cancer Inst. 2004 Dec 1;96(23):1769-80. doi: 10.1093/jnci/djh322.
• [86] Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium. Arthritis Rheumatol. 2014 Jan;66(1):15-23.
• [87] mTOR inhibition reverses acquired endocrine therapy resistance of breast cancer cells at the cell proliferation and gene-expression levels. Cancer Sci. 2008 Oct;99(10):1992-2003. doi: 10.1111/j.1349-7006.2008.00955.x.
• [88] Leptomycin B reduces primary and acquired resistance of gefitinib in lung cancer cells. Toxicol Appl Pharmacol. 2017 Nov 15;335:16-27. doi: 10.1016/j.taap.2017.09.017. Epub 2017 Sep 21.
• [89] Assessment of the cytotoxic, genotoxic, and apoptotic potential of flurbiprofen in HeLa and HepG2 cell lines. J Biochem Mol Toxicol. 2021 Jun;35(6):1-11. doi: 10.1002/jbt.22770. Epub 2021 Mar 11.
• [90] Apoptotic signaling pathways induced by nitric oxide in human lymphoblastoid cells expressing wild-type or mutant p53. Cancer Res. 2004 May 1;64(9):3022-9. doi: 10.1158/0008-5472.can-03-1880.
• [91] Bexarotene activates the p53/p73 pathway in human cutaneous T-cell lymphoma. Br J Dermatol. 2009 Mar;160(3):519-26. doi: 10.1111/j.1365-2133.2008.08931.x. Epub 2008 Nov 25.
• [92] Expression profile analysis of colon cancer cells in response to sulindac or aspirin. Biochem Biophys Res Commun. 2002 Mar 29;292(2):498-512.
• [93] Apoptotic induction by simvastatin in human lung cancer A549 cells via Akt signaling dependent down-regulation of survivin. Invest New Drugs. 2011 Oct;29(5):945-52. doi: 10.1007/s10637-010-9450-2. Epub 2010 May 13.
• [94] Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells. Oncogene. 2005 Sep 15;24(41):6213-21. doi: 10.1038/sj.onc.1208774.
• [95] Quercetin inhibit human SW480 colon cancer growth in association with inhibition of cyclin D1 and survivin expression through Wnt/beta-catenin signaling pathway. Cancer Invest. 2009 Jul;27(6):604-12. doi: 10.1080/07357900802337191.
• [96] Troglitazone sensitizes tumor cells to TRAIL-induced apoptosis via down-regulation of FLIP and Survivin. Apoptosis. 2006 Sep;11(9):1503-12. doi: 10.1007/s10495-006-8896-3.
• [97] Oxidative stress modulates theophylline effects on steroid responsiveness. Biochem Biophys Res Commun. 2008 Dec 19;377(3):797-802.
• [98] The antipsychotic chlorpromazine suppresses YAP signaling, stemness properties, and drug resistance in breast cancer cells. Chem Biol Interact. 2019 Apr 1;302:28-35. doi: 10.1016/j.cbi.2019.01.033. Epub 2019 Jan 28.
• [99] Endoplasmic reticulum stress and MAPK signaling pathway activation underlie leflunomide-induced toxicity in HepG2 Cells. Toxicology. 2017 Dec 1;392:11-21.
• [100] Stem cell transcriptome responses and corresponding biomarkers that indicate the transition from adaptive responses to cytotoxicity. Chem Res Toxicol. 2017 Apr 17;30(4):905-922.
• [101] Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
• [102] Promoter hypermethylation-mediated down-regulation of LATS1 and LATS2 in human astrocytoma. Neurosci Res. 2006 Dec;56(4):450-8. doi: 10.1016/j.neures.2006.09.006. Epub 2006 Oct 17.
• [103] Suppression of cancer relapse and metastasis by inhibiting cancer stemness. Proc Natl Acad Sci U S A. 2015 Feb 10;112(6):1839-44. doi: 10.1073/pnas.1424171112. Epub 2015 Jan 20.
• [104] Genomic profiling uncovers a molecular pattern for toxicological characterization of mutagens and promutagens in vitro. Toxicol Sci. 2011 Jul;122(1):185-97.
• [105] Quercetin inhibits invasion, migration and signalling molecules involved in cell survival and proliferation of prostate cancer cell line (PC-3). Cell Biochem Funct. 2011 Mar;29(2):87-95. doi: 10.1002/cbf.1725. Epub 2011 Feb 9.
• [106] Phenotypic characterization of retinoic acid differentiated SH-SY5Y cells by transcriptional profiling. PLoS One. 2013 May 28;8(5):e63862.
• [107] A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015 Sep;89(9):1599-618.
• [108] Arsenic trioxide (As2O3) inhibits invasion of HT1080 human fibrosarcoma cells: role of nuclear factor-kappaB and reactive oxygen species. J Cell Biochem. 2005 Aug 1;95(5):955-69. doi: 10.1002/jcb.20452.
• [109] Atorvastatin affects several angiogenic mediators in human endothelial cells. Endothelium. 2005 Sep-Dec;12(5-6):233-41.
• [110] Cannabidiol-induced transcriptomic changes and cellular senescence in human Sertoli cells. Toxicol Sci. 2023 Feb 17;191(2):227-238. doi: 10.1093/toxsci/kfac131.
• [111] G2 delay induced by nitrogen mustard in human cells affects cyclin A/cdk2 and cyclin B1/cdc2-kinase complexes differently. J Biol Chem. 1993 Apr 15;268(11):8298-308.
• [112] Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203. doi: 10.1093/toxsci/kfp309. Epub 2009 Dec 31.
• [113] Selenite and selenomethionine promote HL-60 cell cycle progression. J Nutr. 2002 Apr;132(4):674-9. doi: 10.1093/jn/132.4.674.
• [114] Differential gene expression of sulindac-treated human breast epithelial cells. Int J Oncol. 2005 Dec;27(6):1727-36.
• [115] Functional gene expression profile underlying methotrexate-induced senescence in human colon cancer cells. Tumour Biol. 2011 Oct;32(5):965-76.
• [116] Inhibition of prostate cancer cell colony formation by the flavonoid quercetin correlates with modulation of specific regulatory genes. Clin Diagn Lab Immunol. 2004 Jan;11(1):63-9. doi: 10.1128/cdli.11.1.63-69.2004.
• [117] Cannabidiol enhances cytotoxicity of anti-cancer drugs in human head and neck squamous cell carcinoma. Sci Rep. 2020 Nov 26;10(1):20622. doi: 10.1038/s41598-020-77674-y.
• [118] Evidence of securin-mediated resistance to gefitinib-induced apoptosis in human cancer cells. Chem Biol Interact. 2013 Apr 25;203(2):412-22. doi: 10.1016/j.cbi.2013.03.011. Epub 2013 Mar 22.
• [119] Cigarette smoke and asbestos activate poly-ADP-ribose polymerase in alveolar epithelial cells. J Investig Med. 2001 Jan;49(1):68-76. doi: 10.2310/6650.2001.34092.
• [120] The antidepressants imipramine, clomipramine, and citalopram induce apoptosis in human acute myeloid leukemia HL-60 cells via caspase-3 activation. J Biochem Mol Toxicol. 1999;13(6):338-47. doi: 10.1002/(sici)1099-0461(1999)13:6<338::aid-jbt8>3.0.co;2-7.
• [121] Ciprofloxacin mediated cell growth inhibition, S/G2-M cell cycle arrest, and apoptosis in a human transitional cell carcinoma of the bladder cell line. Clin Cancer Res. 2000 Mar;6(3):891-900.
• [122] Investigation of molecular mechanisms underlying the antiproliferative effects of colchicine against PC3 prostate cancer cells. Toxicol In Vitro. 2021 Jun;73:105138. doi: 10.1016/j.tiv.2021.105138. Epub 2021 Mar 6.
• [123] Sulindac enhances adenoviral vector expressing mda-7/IL-24-mediated apoptosis in human lung cancer. Mol Cancer Ther. 2005 Feb;4(2):291-304.
• [124] Methotrexate induces poly(ADP-ribose) polymerase-dependent, caspase 3-independent apoptosis in subsets of proliferating CD4+ T cells. Clin Exp Immunol. 2007 May;148(2):288-95. doi: 10.1111/j.1365-2249.2007.03335.x. Epub 2007 Feb 7.
• [125] 4.8% sevoflurane induces activation of autophagy in human neuroblastoma SH-SY5Y cells by the AMPK/mTOR signaling pathway. Neurotoxicology. 2022 May;90:256-264. doi: 10.1016/j.neuro.2022.04.008. Epub 2022 Apr 23.
• [126] Enhanced chemotherapeutic efficacy of docetaxel in human lung cancer cell line via GLUT1 inhibitor. J Biochem Mol Toxicol. 2023 Jun;37(6):e23348. doi: 10.1002/jbt.23348. Epub 2023 Mar 31.
• [127] Breast cancer cells response to the antineoplastic agents cisplatin, carboplatin, and doxorubicin at the mRNA expression levels of distinct apoptosis-related genes, including the new member, BCL2L12. Ann N Y Acad Sci. 2007 Jan;1095:35-44. doi: 10.1196/annals.1397.005.
• [128] Extracellular signal-regulated kinase activation and Bcl-2 downregulation mediate apoptosis after gemcitabine treatment partly via a p53-independent pathway. Eur J Pharmacol. 2004 Oct 19;502(3):169-83. doi: 10.1016/j.ejphar.2004.09.006.
• [129] Verapamil potentiates anti-glioblastoma efficacy of temozolomide by modulating apoptotic signaling. Toxicol In Vitro. 2018 Oct;52:306-313. doi: 10.1016/j.tiv.2018.07.001. Epub 2018 Jul 9.
• [130] Inhibition of caspase-dependent mitochondrial permeability transition protects airway epithelial cells against mustard-induced apoptosis. Apoptosis. 2006 Sep;11(9):1545-59. doi: 10.1007/s10495-006-8764-1.
• [131] Sertraline, an antidepressant, induces apoptosis in hepatic cells through the mitogen-activated protein kinase pathway. Toxicol Sci. 2014 Feb;137(2):404-15. doi: 10.1093/toxsci/kft254. Epub 2013 Nov 5.
• [132] -Carotene Induces Apoptosis in Human Esophageal Squamous Cell Carcinoma Cell Lines via the Cav-1/AKT/NF-B Signaling Pathway. J Biochem Mol Toxicol. 2016 Mar;30(3):148-57. doi: 10.1002/jbt.21773. Epub 2016 Jan 6.
• [133] Gene expression profiles with activation of the estrogen receptor alpha-selective estrogen receptor modulator complex in breast cancer cells expressing wild-type estrogen receptor. Cancer Res. 2002 Aug 1;62(15):4419-26.
• [134] Synthesis and antitumor evaluation of nitrovinyl biphenyls: anticancer agents based on allocolchicines. ChemMedChem. 2011 May 2;6(5):859-68. doi: 10.1002/cmdc.201100019. Epub 2011 Apr 6.
• [135] Methotrexate modulates folate phenotype and inflammatory profile in EA.hy 926 cells. Eur J Pharmacol. 2014 Jun 5;732:60-7.
• [136] Rapamycin sensitizes multiple myeloma cells to apoptosis induced by dexamethasone. Blood. 2004 Apr 15;103(8):3138-47. doi: 10.1182/blood-2003-05-1543. Epub 2003 Dec 24.
• [137] Antidepressant drug sertraline modulates AMPK-MTOR signaling-mediated autophagy via targeting mitochondrial VDAC1 protein. Autophagy. 2021 Oct;17(10):2783-2799. doi: 10.1080/15548627.2020.1841953. Epub 2020 Nov 9.
• [138] EGFR tyrosine kinase inhibitors activate autophagy as a cytoprotective response in human lung cancer cells. PLoS One. 2011;6(6):e18691. doi: 10.1371/journal.pone.0018691. Epub 2011 Jun 2.
• [139] Oxidative stress induces parallel autophagy and mitochondria dysfunction in human glioma U251 cells. Toxicol Sci. 2009 Aug;110(2):376-88. doi: 10.1093/toxsci/kfp101. Epub 2009 May 18.
• [140] Combination small molecule MEK and PI3K inhibition enhances uveal melanoma cell death in a mutant GNAQ- and GNA11-dependent manner. Clin Cancer Res. 2012 Aug 15;18(16):4345-55. doi: 10.1158/1078-0432.CCR-11-3227. Epub 2012 Jun 25.
• [141] Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
• [142] SU5416 inhibited VEGF and HIF-1alpha expression through the PI3K/AKT/p70S6K1 signaling pathway. Biochem Biophys Res Commun. 2004 Nov 12;324(2):471-80. doi: 10.1016/j.bbrc.2004.09.082.
• [143] Differential modulation of PI3-kinase/Akt pathway during all-trans retinoic acid- and Am80-induced HL-60 cell differentiation revealed by DNA microarray analysis. Biochem Pharmacol. 2004 Dec 1;68(11):2177-86.
• [144] D-glucosamine down-regulates HIF-1alpha through inhibition of protein translation in DU145 prostate cancer cells. Biochem Biophys Res Commun. 2009 Apr 24;382(1):96-101. doi: 10.1016/j.bbrc.2009.02.129. Epub 2009 Feb 28.
• [145] Arsenic trioxide inhibits translation of mRNA of bcr-abl, resulting in attenuation of Bcr-Abl levels and apoptosis of human leukemia cells. Cancer Res. 2003 Nov 15;63(22):7950-8.
• [146] The nonsteroidal anti-inflammatory drugs aspirin and indomethacin attenuate beta-catenin/TCF-4 signaling. Oncogene. 2001 Feb 1;20(5):645-53. doi: 10.1038/sj.onc.1204123.
• [147] Novel mechanism of cannabidiol-induced apoptosis in breast cancer cell lines. Breast. 2018 Oct;41:34-41. doi: 10.1016/j.breast.2018.06.009. Epub 2018 Jun 22.
• [148] Cross-talk between non-genomic and genomic signalling pathways--distinct effect profiles of environmental estrogens. Toxicol Appl Pharmacol. 2010 Jun 1;245(2):160-70. doi: 10.1016/j.taap.2010.02.015. Epub 2010 Mar 4.
• [149] Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival. Cancer Res. 2006 Jun 1;66(11):5542-8. doi: 10.1158/0008-5472.CAN-05-4620.
• [150] BMN 673 (talazoparib): A potent PARP inhibitor for triple negative breast cancer with different genetic profile. J Biochem Mol Toxicol. 2019 May;33(5):e22286. doi: 10.1002/jbt.22286. Epub 2019 Jan 23.
• [151] Resveratrol attenuates senescence of adipose-derived mesenchymal stem cells and restores their paracrine effects on promoting insulin secretion of INS-1 cells through Pim-1. Eur Rev Med Pharmacol Sci. 2016;20(6):1203-13.
• [152] Ribavirin augments doxorubicin's efficacy in human hepatocellular carcinoma through inhibiting doxorubicin-induced eIF4E activation. J Biochem Mol Toxicol. 2018 Jan;32(1). doi: 10.1002/jbt.22007. Epub 2017 Nov 7.
• [153] Cell cycle effects of nonsteroidal anti-inflammatory drugs and enhanced growth inhibition in combination with gemcitabine in pancreatic carcinoma cells. J Pharmacol Exp Ther. 2001 Sep;298(3):976-85.
• [154] Beta-carotene and apocarotenals promote retinoid signaling in BEAS-2B human bronchioepithelial cells. Arch Biochem Biophys. 2006 Nov 1;455(1):48-60.
• [155] Topotecan and methotrexate alter expression of the apoptosis-related genes BCL2, FAS and BCL2L12 in leukemic HL-60 cells. Biol Chem. 2006 Dec;387(12):1629-33. doi: 10.1515/BC.2006.203.
• [156] Carvedilol prevents epinephrine-induced apoptosis in human coronary artery endothelial cells: modulation of Fas/Fas ligand and caspase-3 pathway. Cardiovasc Res. 2000 Feb;45(3):788-94. doi: 10.1016/s0008-6363(99)00369-7.
• [157] Multifaceted preventive effects of single agent quercetin on a human prostate adenocarcinoma cell line (PC-3): implications for nutritional transcriptomics and multi-target therapy. Med Oncol. 2011 Dec;28(4):1395-404. doi: 10.1007/s12032-010-9603-3. Epub 2010 Jul 2.
• [158] Regulatory role of KEAP1 and NRF2 in PPAR expression and chemoresistance in human non-small-cell lung carcinoma cells. Free Radic Biol Med. 2012 Aug 15;53(4):758-68. doi: 10.1016/j.freeradbiomed.2012.05.041. Epub 2012 Jun 7.
• [159] Non-nutritional sweeteners effects on endothelial vascular function. Toxicol In Vitro. 2020 Feb;62:104694. doi: 10.1016/j.tiv.2019.104694. Epub 2019 Oct 23.
• [160] Transcriptome-based functional classifiers for direct immunotoxicity. Arch Toxicol. 2014 Mar;88(3):673-89.
• [161] Treatment with anticancer agents induces dysregulation of specific Wnt signaling pathways in human ovarian luteinized granulosa cells in vitro. Toxicol Sci. 2013 Nov;136(1):183-92. doi: 10.1093/toxsci/kft175. Epub 2013 Aug 16.
• [162] Progesterone increases csk homologous kinase in HMC-1560 human mast cells and reduces cell proliferation. J Cell Biochem. 2007 Dec 1;102(5):1271-80. doi: 10.1002/jcb.21357.
• [163] Cannabidiol upregulates melanogenesis through CB1 dependent pathway by activating p38 MAPK and p42/44 MAPK. Chem Biol Interact. 2017 Aug 1;273:107-114. doi: 10.1016/j.cbi.2017.06.005. Epub 2017 Jun 7.
• [164] Growth stimulation of human pulmonary adenocarcinoma cells and small airway epithelial cells by beta-carotene via activation of cAMP, PKA, CREB and ERK1/2. Int J Cancer. 2006 Mar 15;118(6):1370-80. doi: 10.1002/ijc.21537.
• [165] Estrogen and pure antiestrogen fulvestrant (ICI 182 780) augment cell-matrigel adhesion of MCF-7 breast cancer cells through a novel G protein coupled estrogen receptor (GPR30)-to-calpain signaling axis. Toxicol Appl Pharmacol. 2014 Mar 1;275(2):176-81. doi: 10.1016/j.taap.2014.01.005. Epub 2014 Jan 17.
• [166] Inhibition of activator protein 1 by barbiturates is mediated by differential effects on mitogen-activated protein kinases and the small G proteins ras and rac-1. J Pharmacol Exp Ther. 2004 Dec;311(3):1232-40. doi: 10.1124/jpet.104.071332. Epub 2004 Jul 19.
• [167] Growth of hormone-dependent MCF-7 breast cancer cells is promoted by constitutive caveolin-1 whose expression is lost in an EGF-R-mediated manner during development of tamoxifen resistance. Breast Cancer Res Treat. 2010 Feb;119(3):575-91. doi: 10.1007/s10549-009-0355-8. Epub 2009 Mar 15.
• [168] Effect of histamine H1 receptor antagonists on TARC/CCL17 and MDC/CCL22 production from CD14+ cells induced by antigenic stimulation in vitro. Int Arch Allergy Immunol. 2011;155(1):38-51. doi: 10.1159/000318720. Epub 2010 Nov 25.
• [169] SIRT3 Mediates the Antioxidant Effect of Hydrogen Sulfide in Endothelial Cells. Antioxid Redox Signal. 2016 Feb 20;24(6):329-43. doi: 10.1089/ars.2015.6331. Epub 2015 Nov 10.
• [170] Downregulation of mitogen-activated protein kinases (MAPKs) in chronic ethanol-induced fatty liver. Toxicol Mech Methods. 2020 Jul;30(6):407-416. doi: 10.1080/15376516.2020.1747126. Epub 2020 Apr 1.
• [171] A unique mechanism of beta-blocker action: carvedilol stimulates beta-arrestin signaling. Proc Natl Acad Sci U S A. 2007 Oct 16;104(42):16657-62. doi: 10.1073/pnas.0707936104. Epub 2007 Oct 9.
• [172] The stent-eluting drugs sirolimus and paclitaxel suppress healing of the endothelium by induction of autophagy. Am J Pathol. 2009 Nov;175(5):2226-34.
• [173] Modulation of apoptosis in HaCaT keratinocytes via differential regulation of ERK signaling pathway by flavonoids. J Biol Chem. 2005 Sep 9;280(36):31498-507. doi: 10.1074/jbc.M505537200. Epub 2005 Jul 13.
• [174] Arsenite and cadmium promote the development of mammary tumors. Carcinogenesis. 2020 Jul 14;41(7):1005-1014. doi: 10.1093/carcin/bgz176.
• [175] Unique signatures of stress-induced senescent human astrocytes. Exp Neurol. 2020 Dec;334:113466. doi: 10.1016/j.expneurol.2020.113466. Epub 2020 Sep 17.
• [176] Transcriptomic analysis of untreated and drug-treated differentiated HepaRG cells over a 2-week period. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):27-35.
• [177] Retinoic acid receptor alpha amplifications and retinoic acid sensitivity in breast cancers. Clin Breast Cancer. 2013 Oct;13(5):401-8.
• [178] Keratinocyte-derived IL-36gama plays a role in hydroquinone-induced chemical leukoderma through inhibition of melanogenesis in human epidermal melanocytes. Arch Toxicol. 2019 Aug;93(8):2307-2320.
• [179] Inhibiting Heat Shock Proteins Can Potentiate the Cytotoxic Effect of Cannabidiol in Human Glioma Cells. Anticancer Res. 2015 Nov;35(11):5827-37.
• [180] Inhibition of cholesterol metabolism underlies synergy between mTOR pathway inhibition and chloroquine in bladder cancer cells. Oncogene. 2016 Aug 25;35(34):4518-28. doi: 10.1038/onc.2015.511. Epub 2016 Feb 8.
• [181] Nicotine-induced survival signaling in lung cancer cells is dependent on their p53 status while its down-regulation by curcumin is independent. Mol Cancer. 2010 Aug 20;9:220.
• [182] Role of miRNA in the regulation of cannabidiol-mediated apoptosis in neuroblastoma cells. Oncotarget. 2019 Jan 1;10(1):45-59. doi: 10.18632/oncotarget.26534. eCollection 2019 Jan 1.
• [183] Dihydromyricetin suppresses tumor growth via downregulation of the EGFR/Akt/survivin signaling pathway. J Biochem Mol Toxicol. 2023 Jun;37(6):e23328. doi: 10.1002/jbt.23328. Epub 2023 Feb 19.
• [184] Effect of toll-like receptor 7 and 9 targeted therapy to prevent the development of hepatocellular carcinoma. Liver Int. 2015 Mar;35(3):1063-76. doi: 10.1111/liv.12626. Epub 2014 Jul 30.
• [185] Low-expressional IGF1 mediated methimazole-induced liver developmental toxicity in fetal mice. Toxicology. 2018 Sep 1;408:70-79. doi: 10.1016/j.tox.2018.07.004. Epub 2018 Jul 7.
• [186] Zidovudine induces S-phase arrest and cell cycle gene expression changes in human cells. Mutagenesis. 2005 Mar;20(2):139-46. doi: 10.1093/mutage/gei019. Epub 2005 Mar 22.
• [187] Cannabidiol Activates Neuronal Precursor Genes in Human Gingival Mesenchymal Stromal Cells. J Cell Biochem. 2017 Jun;118(6):1531-1546. doi: 10.1002/jcb.25815. Epub 2016 Dec 29.
• [188] Glucocorticoids induce G1 arrest of lymphoblastic cells through retinoblastoma protein Rb1 dephosphorylation in childhood acute lymphoblastic leukemia in vivo. Cancer Biol Ther. 2004 May;3(5):470-6. doi: 10.4161/cbt.3.5.838. Epub 2004 May 9.
• [189] Different apoptosis ratios and gene expressions in two human cell lines after sevoflurane anaesthesia. Acta Anaesthesiol Scand. 2009 Oct;53(9):1192-9. doi: 10.1111/j.1399-6576.2009.02036.x. Epub 2009 Jun 30.
• [190] [Mechanisms underlying the effect of arsenic trioxide on proliferation inhibition and apoptosis induction in myeloma cell line u266]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2007 Oct;15(5):982-5.
• [191] Lovastatin lactone elicits human lung cancer cell apoptosis via a COX-2/PPAR-dependent pathway. Oncotarget. 2016 Mar 1;7(9):10345-62. doi: 10.18632/oncotarget.7213.
• [192] Induction of apoptosis by cidofovir in human papillomavirus (HPV)-positive cells. Oncol Res. 2000;12(9-10):397-408. doi: 10.3727/096504001108747855.
• [193] Comparison of burst of reactive oxygen species and activation of caspase-3 in apoptosis of K562 and HL-60 cells induced by docetaxel. Cancer Lett. 2004 Oct 8;214(1):103-13. doi: 10.1016/j.canlet.2004.03.047.
• [194] Induction of mitochondrial manganese superoxide dismutase confers resistance to apoptosis in acute myeloblastic leukaemia cells exposed to etoposide. Br J Haematol. 2000 Mar;108(3):574-81. doi: 10.1046/j.1365-2141.2000.01852.x.
• [195] Cisplatin-enhanced sensitivity of glioblastoma multiforme U251 cells to adenovirus-delivered TRAIL in vitro. Tumour Biol. 2010 Dec;31(6):613-22. doi: 10.1007/s13277-010-0077-x. Epub 2010 Jul 11.
• [196] Insulin-like growth factor I is the key growth factor in serum that protects neuroblastoma cells from hyperosmotic-induced apoptosis. J Cell Physiol. 2000 Jan;182(1):24-32. doi: 10.1002/(SICI)1097-4652(200001)182:1<24::AID-JCP3>3.0.CO;2-6.
• [197] mRNA expression analysis of a variety of apoptosis-related genes, including the novel gene of the BCL2-family, BCL2L12, in HL-60 leukemia cells after treatment with carboplatin and doxorubicin. Biol Chem. 2004 Nov;385(11):1099-103. doi: 10.1515/BC.2004.143.
• [198] Neurokinin-1 receptor (NK1R) inhibition sensitizes APL cells to anti-tumor effect of arsenic trioxide via restriction of NF-B axis: Shedding new light on resistance to Aprepitant. Int J Biochem Cell Biol. 2018 Oct;103:105-114. doi: 10.1016/j.biocel.2018.08.010. Epub 2018 Aug 23.
• [199] Cisplatin induces autophagy to enhance hepatitis B virus replication via activation of ROS/JNK and inhibition of the Akt/mTOR pathway. Free Radic Biol Med. 2019 Feb 1;131:225-236. doi: 10.1016/j.freeradbiomed.2018.12.008. Epub 2018 Dec 11.
• [200] Inhibition of autophagic flux differently modulates cannabidiol-induced death in 2D and 3D glioblastoma cell cultures. Sci Rep. 2020 Feb 14;10(1):2687. doi: 10.1038/s41598-020-59468-4.
• [201] Frankincense myrrh attenuates hepatocellular carcinoma by regulating tumor blood vessel development through multiple epidermal growth factor receptor-mediated signaling pathways. World J Gastrointest Oncol. 2022 Feb 15;14(2):450-477. doi: 10.4251/wjgo.v14.i2.450.
• [202] Neuroprotective effects of glucomoringin-isothiocyanate against H(2)O(2)-Induced cytotoxicity in neuroblastoma (SH-SY5Y) cells. Neurotoxicology. 2019 Dec;75:89-104. doi: 10.1016/j.neuro.2019.09.008. Epub 2019 Sep 12.
• [203] Nocodazole-induced p53-dependent c-Jun N-terminal kinase activation reduces apoptosis in human colon carcinoma HCT116 cells. J Biol Chem. 2002 Nov 15;277(46):43648-58. doi: 10.1074/jbc.M203214200. Epub 2002 Sep 6.
• [204] Quercetin potentiates apoptosis by inhibiting nuclear factor-kappaB signaling in H460 lung cancer cells. Biol Pharm Bull. 2013;36(6):944-51. doi: 10.1248/bpb.b12-01004.
• [205] Lon protease and eiF2 are involved in acute, but not prolonged, antiretroviral induced stress response in HepG2 cells. Chem Biol Interact. 2016 May 25;252:82-6. doi: 10.1016/j.cbi.2016.03.021. Epub 2016 Apr 1.
• [206] Disease-modifying effects of glucosamine HCl involving regulation of metalloproteinases and chemokines activated by interleukin-1beta in human primary synovial fibroblasts. J Cell Biochem. 2008 May 1;104(1):38-50. doi: 10.1002/jcb.21597.
• [207] Characterization of cell death induced by ethacrynic acid in a human colon cancer cell line DLD-1 and suppression by N-acetyl-L-cysteine. Cancer Sci. 2003 Oct;94(10):886-93.
• [208] Microarray analysis of H2O2-, HNE-, or tBH-treated ARPE-19 cells. Free Radic Biol Med. 2002 Nov 15;33(10):1419-32.
• [209] Methotrexate increases expression of cell cycle checkpoint genes via JNK activation. Arthritis Rheum. 2012 Jun;64(6):1780-9. doi: 10.1002/art.34342. Epub 2011 Dec 19.
• [210] Synergistic promotion of breast cancer cells death by targeting molecular chaperone GRP78 and heat shock protein 70. J Cell Mol Med. 2009 Nov-Dec;13(11-12):4540-50. doi: 10.1111/j.1582-4934.2008.00575.x.
• [211] Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
• [212] Arsenic trioxide induces apoptosis in chronic myelogenous leukemia K562 cells: possible involvement of p38 MAP kinase. J Biochem Mol Biol. 2002 Jul 31;35(4):377-83. doi: 10.5483/bmbrep.2002.35.4.377.
• [213] Intracellular mobility and nuclear trafficking of the stress-activated kinase JNK1 are impeded by hyperosmotic stress. Biochim Biophys Acta. 2014 Feb;1843(2):253-64. doi: 10.1016/j.bbamcr.2013.10.017. Epub 2013 Nov 1.
• [214] Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
• [215] Response rate of fibrosarcoma cells to cytotoxic drugs on the expression level correlates to the therapeutic response rate of fibrosarcomas and is mediated by regulation of apoptotic pathways. BMC Cancer. 2005 Jul 7;5:74. doi: 10.1186/1471-2407-5-74.
• [216] Integrated assessment by multiple gene expression analysis of quercetin bioactivity on anticancer-related mechanisms in colon cancer cells in vitro. Eur J Nutr. 2005 Mar;44(3):143-56. doi: 10.1007/s00394-004-0503-1. Epub 2004 Apr 30.
• [217] The exosome-like vesicles derived from androgen exposed-prostate stromal cells promote epithelial cells proliferation and epithelial-mesenchymal transition. Toxicol Appl Pharmacol. 2021 Jan 15;411:115384. doi: 10.1016/j.taap.2020.115384. Epub 2020 Dec 25.
• [218] Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
• [219] Repurposing L-menthol for systems medicine and cancer therapeutics? L-menthol induces apoptosis through caspase 10 and by suppressing HSP90. OMICS. 2016 Jan;20(1):53-64.
• [220] Synergistic antimetastatic effect of cotreatment with licochalcone A and sorafenib on human hepatocellular carcinoma cells through the inactivation of MKK4/JNK and uPA expression. Environ Toxicol. 2018 Dec;33(12):1237-1244. doi: 10.1002/tox.22630. Epub 2018 Sep 6.
• [221] [Indomethacin-induced HL-60 leukemic cell apoptosis and the activation of C-jun NH2- terminal kinase signal transduction pathway]. Hunan Yi Ke Da Xue Xue Bao. 2003 Dec;28(6):557-62.
• [222] Estrogen Regulates MAPK-Related Genes through Genomic and Nongenomic Interactions between IGF-I Receptor Tyrosine Kinase and Estrogen Receptor-Alpha Signaling Pathways in Human Uterine Leiomyoma Cells. J Signal Transduct. 2012;2012:204236. doi: 10.1155/2012/204236. Epub 2012 Oct 9.
• [223] Lovastatin induces apoptosis of anaplastic thyroid cancer cells via inhibition of protein geranylgeranylation and de novo protein synthesis. Endocrinology. 2003 Sep;144(9):3852-9. doi: 10.1210/en.2003-0098.
• [224] Insulin-like growth factor I prevents mannitol-induced degradation of focal adhesion kinase and Akt. J Biol Chem. 2002 Jul 26;277(30):27393-400. doi: 10.1074/jbc.M201963200. Epub 2002 May 14.
• [225] Effects of gonadotrophin-releasing hormone agonists on apoptosis of granulosa cells. Ann N Y Acad Sci. 2005 May;1042:531-7. doi: 10.1196/annals.1338.065.
• [226] The effects of quercetin in cultured human RPE cells under oxidative stress and in Ccl2/Cx3cr1 double deficient mice. Exp Eye Res. 2010 Jul;91(1):15-25.
• [227] Inhibiting AKT signaling pathway with cilostazol and meloxicam synergism for suppressing K562 cells in vitro. J Biochem Mol Toxicol. 2022 Nov;36(11):e23185. doi: 10.1002/jbt.23185. Epub 2022 Aug 3.
• [228] Ciprofloxacin induces apoptosis and inhibits proliferation of human colorectal carcinoma cells. Br J Cancer. 2002 Feb 1;86(3):443-8. doi: 10.1038/sj.bjc.6600079.
• [229] Colchicine-induced apoptosis in human normal liver L-02 cells by mitochondrial mediated pathways. Toxicol In Vitro. 2012 Aug;26(5):649-55. doi: 10.1016/j.tiv.2012.01.024. Epub 2012 Feb 8.
• [230] Prevention of deoxycholate-induced gastric apoptosis by aspirin: roles of NF-kappaB and PKC signaling. J Surg Res. 2008 Mar;145(1):66-73. doi: 10.1016/j.jss.2007.04.039. Epub 2007 Jul 20.
• [231] Pharmacotoxicology of clinically-relevant concentrations of obeticholic acid in an organotypic human hepatocyte system. Toxicol In Vitro. 2017 Mar;39:93-103.
• [232] Overexpression of protein kinase C-beta1 isoenzyme suppresses indomethacin-induced apoptosis in gastric epithelial cells. Gastroenterology. 2000 Mar;118(3):507-14. doi: 10.1016/s0016-5085(00)70256-3.
• [233] Prenatal arsenic exposure and the epigenome: identifying sites of 5-methylcytosine alterations that predict functional changes in gene expression in newborn cord blood and subsequent birth outcomes. Toxicol Sci. 2015 Jan;143(1):97-106. doi: 10.1093/toxsci/kfu210. Epub 2014 Oct 10.
• [234] Effects of progesterone treatment on expression of genes involved in uterine quiescence. Reprod Sci. 2011 Aug;18(8):781-97.
• [235] Ethyl carbamate induces cell death through its effects on multiple metabolic pathways. Chem Biol Interact. 2017 Nov 1;277:21-32.
• [236] Combining kallistatin gene therapy and meloxicam to treat hepatocellular carcinoma in mice. Cancer Sci. 2009 Nov;100(11):2226-33. doi: 10.1111/j.1349-7006.2009.01306.x. Epub 2009 Aug 4.
• [237] Characterization of formaldehyde's genotoxic mode of action by gene expression analysis in TK6 cells. Arch Toxicol. 2013 Nov;87(11):1999-2012.
• [238] Clinical determinants of response to irinotecan-based therapy derived from cell line models. Clin Cancer Res. 2008 Oct 15;14(20):6647-55.
• [239] Predictive toxicology using systemic biology and liver microfluidic "on chip" approaches: application to acetaminophen injury. Toxicol Appl Pharmacol. 2012 Mar 15;259(3):270-80.
• [240] Activation of sterile20-like kinase 1 in proteasome inhibitor bortezomib-induced apoptosis in oncogenic K-ras-transformed cells. Cancer Res. 2006 Jun 15;66(12):6072-9. doi: 10.1158/0008-5472.CAN-06-0125.
• [241] Cannabidiol Modulates the Expression of Alzheimer's Disease-Related Genes in Mesenchymal Stem Cells. Int J Mol Sci. 2016 Dec 23;18(1):26. doi: 10.3390/ijms18010026.
• [242] DNA methylome-wide alterations associated with estrogen receptor-dependent effects of bisphenols in breast cancer. Clin Epigenetics. 2019 Oct 10;11(1):138. doi: 10.1186/s13148-019-0725-y.
• [243] In vitro and in vivo irinotecan-induced changes in expression profiles of cell cycle and apoptosis-associated genes in acute myeloid leukemia cells. Mol Cancer Ther. 2005 Jun;4(6):885-900.
• [244] The NRF2-mediated oxidative stress response pathway is associated with tumor cell resistance to arsenic trioxide across the NCI-60 panel. BMC Med Genomics. 2010 Aug 13;3:37. doi: 10.1186/1755-8794-3-37.
• [245] Differential expression of genes induced by resveratrol in LNCaP cells: P53-mediated molecular targets. Int J Cancer. 2003 Mar 20;104(2):204-12.
• [246] Statins activate the mitochondrial pathway of apoptosis in human lymphoblasts and myeloma cells. Carcinogenesis. 2005 May;26(5):883-91. doi: 10.1093/carcin/bgi036. Epub 2005 Feb 10.
• [247] Drug-induced caspase 8 upregulation sensitises cisplatin-resistant ovarian carcinoma cells to rhTRAIL-induced apoptosis. Br J Cancer. 2011 Apr 12;104(8):1278-87. doi: 10.1038/bjc.2011.84.
• [248] Essential role of caspase-8 in p53/p73-dependent apoptosis induced by etoposide in head and neck carcinoma cells. Mol Cancer. 2011 Jul 31;10:95. doi: 10.1186/1476-4598-10-95.
• [249] The anti-cancer drug gefitinib accelerates Fas-mediated apoptosis by enhancing caspase-8 activation in cancer cells. J Toxicol Sci. 2019;44(6):435-440. doi: 10.2131/jts.44.435.
• [250] Melatonin enhances hydrogen peroxide-induced apoptosis in human promyelocytic leukaemia HL-60 cells. Mol Cell Biochem. 2011 Jul;353(1-2):167-76. doi: 10.1007/s11010-011-0783-8. Epub 2011 Mar 23.
• [251] The contribution of methotrexate exposure and host factors on transcriptional variance in human liver. Toxicol Sci. 2007 Jun;97(2):582-94.
• [252] Increased expression of VDAC1 sensitizes carcinoma cells to apoptosis induced by DNA cross-linking agents. Biochem Pharmacol. 2012 May 1;83(9):1172-82. doi: 10.1016/j.bcp.2012.01.017. Epub 2012 Jan 21.
• [253] Sulindac-derived reactive oxygen species induce apoptosis of human multiple myeloma cells via p38 mitogen activated protein kinase-induced mitochondrial dysfunction. Apoptosis. 2007 Jan;12(1):195-209. doi: 10.1007/s10495-006-0527-5.
• [254] Inhibition of lung cancer cell growth by quercetin glucuronides via G2/M arrest and induction of apoptosis. Drug Metab Dispos. 2006 Feb;34(2):296-304. doi: 10.1124/dmd.105.005280. Epub 2005 Nov 9.
• [255] Levamisole induced apoptosis in cultured vascular endothelial cells. Br J Pharmacol. 2000 Dec;131(8):1577-83.
• [256] Arsenic trioxide (As(2)O(3)) induced apoptosis and its mechanisms in a human esophageal squamous carcinoma cell line. Chin Med J (Engl). 2002 Feb;115(2):280-5.
• [257] Non-steroidal anti-inflammatory drugs induce apoptosis in gastric cancer cells through up-regulation of bax and bak. Carcinogenesis. 2001 Sep;22(9):1393-7. doi: 10.1093/carcin/22.9.1393.
• [258] AMPK activation induced by promethazine increases NOXA expression and Beclin-1 phosphorylation and drives autophagy-associated apoptosis in chronic myeloid leukemia. Chem Biol Interact. 2020 Jan 5;315:108888. doi: 10.1016/j.cbi.2019.108888. Epub 2019 Nov 2.
• [259] Minimal peroxide exposure of neuronal cells induces multifaceted adaptive responses. PLoS One. 2010 Dec 17;5(12):e14352. doi: 10.1371/journal.pone.0014352.
• [260] Quercetin-mediated Mcl-1 and survivin downregulation restores TRAIL-induced apoptosis in non-Hodgkin's lymphoma B cells. Haematologica. 2012 Jan;97(1):38-46. doi: 10.3324/haematol.2011.046466. Epub 2011 Sep 20.
• [261] Increased sensitivity for troglitazone-induced cytotoxicity using a human in vitro co-culture model. Toxicol In Vitro. 2009 Oct;23(7):1387-95.
• [262] Arsenic trioxide promotes histone H3 phosphoacetylation at the chromatin of CASPASE-10 in acute promyelocytic leukemia cells. J Biol Chem. 2002 Dec 20;277(51):49504-10. doi: 10.1074/jbc.M207836200. Epub 2002 Oct 17.
• [263] Susceptibility to drug-induced apoptosis correlates with differential modulation of Bad, Bcl-2 and Bcl-xL protein levels. Cell Death Differ. 2000 Jun;7(6):574-86. doi: 10.1038/sj.cdd.4400688.
• [264] Sulindac sulfide inhibits epidermal growth factor-induced phosphorylation of extracellular-regulated kinase 1/2 and Bad in human colon cancer cells. Cancer Res. 2003 Feb 1;63(3):616-20.
• [265] Simvastatin induces activation of the serine-threonine protein kinase AKT and increases survival of isolated human pancreatic islets. Transplantation. 2002 Oct 27;74(8):1063-9. doi: 10.1097/00007890-200210270-00001.
• [266] Quercetin regulates insulin like growth factor signaling and induces intrinsic and extrinsic pathway mediated apoptosis in androgen independent prostate cancer cells (PC-3). Mol Cell Biochem. 2010 Nov;344(1-2):173-84. doi: 10.1007/s11010-010-0540-4. Epub 2010 Jul 25.
• [267] Down regulation of N-acetylglucosaminyltransferase V facilitates all-transretinoic acid to induce apoptosis of human hepatocarcinoma cells. Mol Cell Biochem. 2006 Mar;284(1-2):103-10. doi: 10.1007/s11010-005-9022-5. Epub 2006 Jan 13.
• [268] Arsenic trioxide induces different gene expression profiles of genes related to growth and apoptosis in glioma cells dependent on the p53 status. Mol Biol Rep. 2008 Sep;35(3):421-9.
• [269] Lunasin, a novel seed peptide, sensitizes human breast cancer MDA-MB-231 cells to aspirin-arrested cell cycle and induced apoptosis. Chem Biol Interact. 2010 Jul 30;186(2):127-34. doi: 10.1016/j.cbi.2010.04.027. Epub 2010 May 21.
• [270] Arsenic suppresses gene expression in promyelocytic leukemia cells partly through Sp1 oxidation. Blood. 2005 Jul 1;106(1):304-10.
• [271] Triggering of transient receptor potential vanilloid type 1 (TRPV1) by capsaicin induces Fas/CD95-mediated apoptosis of urothelial cancer cells in an ATM-dependent manner. Carcinogenesis. 2009 Aug;30(8):1320-9. doi: 10.1093/carcin/bgp138. Epub 2009 Jun 5.
• [272] Methotrexate induces apoptosis through p53/p21-dependent pathway and increases E-cadherin expression through downregulation of HDAC/EZH2. Biochem Pharmacol. 2011 Feb 15;81(4):510-7. doi: 10.1016/j.bcp.2010.11.014. Epub 2010 Nov 27.
• [273] Actinomycin D upregulates proapoptotic protein Puma and downregulates Bcl-2 mRNA in normal peripheral blood lymphocytes. Anticancer Drugs. 2007 Aug;18(7):763-72. doi: 10.1097/CAD.0b013e3280adc905.
• [274] D-Penicillamine targets metastatic melanoma cells with induction of the unfolded protein response (UPR) and Noxa (PMAIP1)-dependent mitochondrial apoptosis. Apoptosis. 2012 Oct;17(10):1079-94.
• [275] Involvement of mitochondrial dysfunction in nefazodone-induced hepatotoxicity. Food Chem Toxicol. 2016 Aug;94:148-58. doi: 10.1016/j.fct.2016.06.001. Epub 2016 Jun 8.
• [276] Improved apoptotic cell death in drug-resistant non-small-cell lung cancer cells by tumor necrosis factor-related apoptosis-inducing ligand-based treatment. J Pharmacol Exp Ther. 2014 Mar;348(3):360-71. doi: 10.1124/jpet.113.210054. Epub 2013 Dec 17.
• [277] Aspirin induces apoptosis in human leukemia cells independently of NF-kappaB and MAPKs through alteration of the Mcl-1/Noxa balance. Apoptosis. 2010 Feb;15(2):219-29. doi: 10.1007/s10495-009-0424-9.
• [278] Effect of organic anion-transporting polypeptide 1B1 (OATP1B1) polymorphism on the single- and multiple-dose pharmacokinetics of enalapril in healthy Chinese adult men. Clin Ther. 2011 May;33(5):655-63. doi: 10.1016/j.clinthera.2011.04.018.
• [279] Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1. Drug Metab Dispos. 2005 Apr;33(4):537-46.
• [280] Omics-based responses induced by bosentan in human hepatoma HepaRG cell cultures. Arch Toxicol. 2018 Jun;92(6):1939-1952.
• [281] Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics. Clin Pharmacol Ther. 2005 Jun;77(6):468-78. doi: 10.1016/j.clpt.2005.01.018.
• [282] SLC19A1, SLC46A1 and SLCO1B1 polymorphisms as predictors of methotrexate-related toxicity in Portuguese rheumatoid arthritis patients. Toxicol Sci. 2014 Nov;142(1):196-209. doi: 10.1093/toxsci/kfu162. Epub 2014 Aug 14.
• [283] SLCO1B1 variants and statin-induced myopathy--a genomewide study. N Engl J Med. 2008 Aug 21;359(8):789-99.
• [284] Transport of fluorescent chenodeoxycholic acid via the human organic anion transporters OATP1B1 and OATP1B3. J Lipid Res. 2006 Jun;47(6):1196-202.
• [285] Transcellular movement of hydroxyurea is mediated by specific solute carrier transporters. Exp Hematol. 2011 Apr;39(4):446-56.
• [286] Severe toxicities after irinotecan-based chemotherapy in a patient with lung cancer: a homozygote for the SLCO1B1*15 allele. Ther Drug Monit. 2007 Oct;29(5):666-8. doi: 10.1097/FTD.0b013e3181357364.